Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders. Discover more about our strategic approaches.
The company is developing a range of pharmaceutical products that are based on new chemical entities and are targeted on skin diseases that can be topically treated.
Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders characterized by severe damage of the gastro-intestinal tract.
Cosmo announces further expansion of endoscopy pipeline with filing for EU approval of New Medical Device Qolotag to enhance diagnosis in sigmoidoscopies
Cosmo makes significant progress in 2016
Cosmo announces details of the successful phase III clinical trials of LuMeBlue™ which will be presented at its R&D day today
Read all news articles
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases.
Read more about us
Share price information
Annual General Meeting
Get in touch with us today.
© 2017 Cosmo pharmaceuticals